Libo Sun

发表

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.

S. Verstovsek, A. Vannucchi, C. Harrison, 2022, Future oncology.

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

E. Vellenga, D. Steensma, P. Fenaux, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

E. Vellenga, D. Steensma, P. Fenaux, 2018, Blood.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

D. Niederwieser, R. Hoffman, A. Vannucchi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

E. Vellenga, D. Steensma, P. Fenaux, 2019, HemaSphere.

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

A. Vannucchi, J. Mascarenhas, R. Komrokji, 2021, Annals of Hematology.

Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC).

A. Santiago-Walker, K. Patel, A. Siefker-Radtke, 2019, Journal of Clinical Oncology.

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

S. Verstovsek, A. Vannucchi, S. Koschmieder, 2022, Blood.

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

S. Verstovsek, R. Mesa, A. Vannucchi, 2020 .

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

E. Vellenga, D. Steensma, P. Fenaux, 2019, Blood.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

P. Fenaux, A. Raza, M. Sekeres, 2022, Blood.

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

E. Vellenga, P. Fenaux, S. Thépot, 2021, Blood.

Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor

M. González-Sales, Y. Wan, T. Berry, 2024, CPT: pharmacometrics & systems pharmacology.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

M. Sekeres, U. Platzbecker, V. Santini, 2023, The Lancet.